mpdl3280a
Showing 1 - 11 of 11
NSCLC Trial in Boston, New York (MPDL3280A, Carboplatin, Nab-paclitaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
- MPDL3280A
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 12, 2022
Locally Advanced or Metastatic Solid Tumors Trial in Groningen (MPDL3280A)
Recruiting
- Locally Advanced or Metastatic Solid Tumors
- MPDL3280A
-
Groningen, NetherlandsUniversity Medical Center Groningen
Feb 28, 2022
Lung Cancer, NSCLC Trial in Houston (MPDL3280A, Carboplatin, Paclitaxel)
Active, not recruiting
- Lung Cancer
- Non-Small Cell Lung Cancer
- MPDL3280A
- +3 more
-
Houston, TexasMD Anderson Cancer Center
Apr 28, 2022
NSCLC Trial in London (MPDL3280A, Vemurafenib, Alectinib)
Recruiting
- Non-small Cell Lung Cancer
- MPDL3280A
- +3 more
-
London, United KingdomUniveristy College London Hospital
Feb 22, 2022
Invasive Ductal Breast Carcinoma Trial in Worldwide (Carboplatin, Abraxane, MPDL3280A)
Active, not recruiting
- Invasive Ductal Breast Carcinoma
- Carboplatin
- +4 more
-
Innsbruck, Austria
- +40 more
Jul 26, 2022
Bladder Cancer Trial in Worldwide (MPDL3280A)
Unknown status
- Bladder Cancer
- MPDL3280A
-
Bordeaux, France
- +19 more
Feb 24, 2020
NSCLC Trial in Santa Monica (Rociletinib, MPDL3280A)
Terminated
- Non-small Cell Lung Cancer
- Rociletinib
- MPDL3280A
-
Santa Monica, CaliforniaUniversity of California at Los Angeles
Jun 28, 2019
NSCLC Trial in Ann Arbor, Seattle (MPDL3280A, Hypofractionated Radiotherapy)
Completed
- Non-small Cell Lung Cancer
- MPDL3280A
- Hypofractionated Radiotherapy
-
Ann Arbor, Michigan
- +1 more
Feb 7, 2019
Small Cell Lung Cancer ( SCLC ) Trial in Washington (Carboplatin, Etoposide, MPDL3280A)
Terminated
- Small Cell Lung Cancer ( SCLC )
- Carboplatin
- +2 more
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Jun 29, 2018
NSCLC Trial in New Haven (CDX-1401, MPDL3280A)
Withdrawn
- Non-Small Cell Lung Cancer
- CDX-1401
- MPDL3280A
-
New Haven, ConnecticutYale University
Jun 21, 2017